#Sweden #gene therapy #Lund #Hansa Biopharma #imlifidase

Hansa Biopharma's Presence at the 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma AB, a notable player in the biopharmaceutical industry, has confirmed its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 2025. This prominent event serves as a platform for healthcare-related companies to discuss innovations and emerging trends. Management representatives from Hansa will elaborate on the company's significant progress and milestones achieved in the past year, particularly in autoimmune diseases, gene therapy, and transplantation.

Key Achievements Over the Past Year

Hansa Biopharma has made substantial strides in its research and portfolio development. Notably, the company has reported promising outcomes from several clinical trials, notably in autoimmune diseases. The 15-HMedIdeS-09 Phase 2 trial focused on Guillain-Barré Syndrome (GBS) has yielded positive results, revealing the potential of imlifidase, the company’s pioneering IgG-cleaving enzyme, in addressing critical medical needs in GBS patients. This success was complemented by the completion of enrollment in the GOOD-IDES-02 Phase 3 trial targeting anti-GBM, alongside impressive findings from the NICE-01 Phase 1 trial involving the second-generation IgG cleaving agent, HNSA-5487. The results indicate a remarkable reduction of IgG levels, showcasing the efficacy and safety of these treatments.

In gene therapy, Hansa initiated two significant trials in collaboration with leading partners. The SRP-9001-104 Phase 1b trial in partnership with Sarepta Therapeutics, Inc. explores treatment for Duchenne Muscular Dystrophy (DMD), while the GNT-018-IDES Phase 2 trial addresses Crigler-Najjar Syndrome. Both trials evaluate the application of imlifidase as a preventive measure against anti-AAV antibodies in patients, signaling a promising direction for gene therapy efficacy.

The company has also reached a milestone in transplantation. The pivotal US Phase 3 trial, ConfIdeS, which investigates the application of imlifidase in kidney transplantation, has successfully completed its randomization phase. Furthermore, Hansa has reported remarkable sales performance for IDEFIRIX, demonstrating the growing recognition and utility of this drug in the European market.

Future Milestones

Hansa Biopharma's outlook for 2025 is filled with potential as it gears up for critical data readouts and regulatory activities. The company will seek to publish results from the pivotal Phase 3 ConfIdeS trial, aiming for a submission of a Biologics License Application (BLA) to the US FDA in the second half of 2025. Other forthcoming reports include results from Sarepta Therapeutics’ Phase 1b trial in DMD and the Good-IDES-02 Phase 3 trial results for anti-GBM disease.

Additionally, Hansa anticipates aligning its development pathway for HNSA-5487 with regulatory bodies, especially targeting neuro-autoimmune diseases such as myasthenia gravis early in 2025.

A Commitment to Innovation

Hansa Biopharma is dedicated to enhancing its robust pipeline of advanced immunomodulating therapies. At the heart of its innovations is its proprietary IgG-cleaving platform designed to tackle IgG-driven immune-mediated diseases. With both imlifidase and HNSA-5487 in its arsenal, Hansa is equipped to address significant unmet medical needs in the realms of autoimmune disorders, gene therapy applications, and transplantation, both in the European market and beyond.

The company's commitment to developing groundbreaking therapies highlights its pivotal role in transforming treatment landscapes for patients suffering from rare and complex diseases. Stakeholders and interested parties are encouraged to reach out for discussions on potential collaborations and insights during the conference.

For more details about Hansa Biopharma and its innovations, potential investors, partners, and attendees can visit their official website or follow them on LinkedIn.